Surrozen SRZN
NASDAQ SRZN
$22.76 +0.22 (+0.98%)
As of: Sep 4, 2026 · 3:59 PM EDT

Surrozen (SRZN) Cash from Financing Activities (2020 - 2026)

Surrozen (SRZN) posted quarterly Cash from Financing Activities of $30.3 million for Q1 2026, down 60.36% year-over-year from $76.4 million in Q1 2025, and up 119.72% quarter-over-quarter from $13.8 million in Q4 2025.

Analysis

Surrozen (SRZN) Cash from Financing Activities (2020 - 2026) Analysis & Trends

Surrozen's Cash from Financing Activities history runs 7 years deep, the most recent figure standing at $30.3 million for Q1 2026.

  • In Q1 2026, Cash from Financing Activities fell 60.36% year-over-year to $30.3 million; the TTM figure through Mar 2026 stood at $38.9 million (down 57.92% YoY), while the FY2025 annual figure was $85.1 million, up 425.79% from the prior year.
  • Cash from Financing Activities for Q1 2026 stood at $30.3 million, up from $13.8 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $76.4 million in Q1 2025, with the low at -$5.1 million in Q2 2025.
  • The 5-year median for Cash from Financing Activities is $9000.0 (2025), against an average of $8.6 million.
  • The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities tumbled 1703.14% in 2022, then soared 15043.96% in 2025.
  • Surrozen's Cash from Financing Activities stood at -$2.5 million in 2022, then jumped by 105.53% to $141000.0 in 2023, then sank by 35.46% to $91000.0 in 2024, then jumped by 15043.96% to $13.8 million in 2025, then surged by 119.72% to $30.3 million in 2026.
  • Business Quant data shows SRZN's Cash from Financing Activities at $30.3 million in Q1 2026, $13.8 million in Q4 2025, and $9000.0 in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 2.42 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - -273.15 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 27.18 Mn
10 Surrozen 263.35 Mn 263.35 Mn - 2.51 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.51 Mn
Mar 31, 2026 30.28 Mn
Dec 31, 2025 13.78 Mn
Sep 30, 2025 9,000.00
Jun 30, 2025 -5.12 Mn
Mar 31, 2025 76.39 Mn
Dec 31, 2024 91,000.00
Sep 30, 2024 -1,000.00
Jun 30, 2024 16.09 Mn
Dec 31, 2023 141,000.00
Sep 30, 2023 -13,000.00
Jun 30, 2023 187,000.00
Mar 31, 2023 -39,000.00
Dec 31, 2022 -2.55 Mn
Sep 30, 2022 -13,000.00
Jun 30, 2022 -3,000.00
Dec 31, 2021 159,000.00
Sep 30, 2021 124.59 Mn
Jun 30, 2021 -314,000.00
Mar 31, 2021 196,000.00